Tefina, a 'female Viagra', currently being studied

Tefina, a ‘female Viagra’, currently being studied
Credit: Aleksandar Todorovic - Fotolia.com

Tefina, the first testosterone based intranasal gel, has been in part developed by the ULg's Galenic Pharmacy Laboratory. It is currently at the stage of testing before being marketed by the Canadian company, Trimel Pharmaceuticals.

The University of Liège's Galenic pharmacy laboratory, directed by Professor Brigitte Evrard, is contributing to the development of the Tefina gel, the first testosterone based intranasal gel. It should be injected, in the form of a , one to two hours before . The nose being an organ rich in , it enables a rapid and targeted absorption of the .

The Liège researchers have been working jointly for two years with the Canadian company, Trimel Pharmaceuticals in the context of developing Tefina. This new drug, which constitutes treatment for female anorgasmia – the impossibility of having an orgasm due to organic, behavioural or psychological reasons – is currently undergoing phase 2 clinical trials in the United States, Canada and Australia. The Canadian company which wants to launch on the market a treatment capable of stimulating desire in women, turned to the Liège laboratory to optimise the product

The University of Liège's Galenic pharmacy laboratory thus developed the composition and formula of an intranasal gel so that a sufficient quantity of testosterone can be administered in a single dose, whilst maintaining the integrity of the nasal epithelium. To ensure optimal activity of the active ingredient it was necessary to solubilise and stabilise it, which proved a genuine challenge for the researchers. The was also studied at the laboratory, which is known for innovating and optimising industrial drug manufacturing processes.

add to favorites email to friend print save as pdf

Related Stories

'Viagra for women' being trialed

Oct 29, 2012

Reaching orgasm remains elusive for nearly 30 per cent of women, but a new ad hoc treatment currently under trial, may drastically reduce that number.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

4 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Tausch
1 / 5 (2) Nov 19, 2012
A new twist to all men are created equal.
Sexual 'equality'?
Oops. Strictly business here.
No selfless, starry-eyed ideals to propagate.